A Phase 1/2 Study of INCB000928 As Monotherapy or Combined with Ruxolitinib (RUX) in Patients (Pts) with Anemia Due to Myelofibrosis (MF)

被引：3

作者：

Mohan, Sanjay R. ^{[1
]}

Oh, Stephen T. ^{[2
]}

Ali, Haris ^{[3
]}

Hunter, Anthony M. ^{[4
]}

Palandri, Francesca ^{[5
]}

Lamothe, Betty ^{[6
]}

Cui, Yi ^{[6
]}

Seguy, Francis ^{[7
]}

McBride, Amanda ^{[6
]}

Savona, Michael Robert ^{[8
]}

Kiladjian, Jean-Jacques ^{[9
]}

Verstovsek, Srdan ^{[10
]}

机构：

[1] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA

[2] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO USA

[3] City Hope Med Ctr, Duarte, CA USA

[4] Emory Univ, Sch Med, Atlanta, GA USA

[5] IRCCS Azienda Osped Univ Bologna, Ist Ematol Seragnoli, Bologna, Italy

[6] Incyte Corp, Wilmington, DE USA

[7] Incyte Biosci Int Sarl, Morges, Switzerland

[8] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[9] Hop St Louis, Paris, France

[10] Univ Texas MD Anderson Canc Ctr, Leukemia Dept, Houston, TX 77030 USA

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-169210

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：3943 / 3944

页数：2

共 50 条

[21] Anemia Burden in Patients With Myelofibrosis (MF) Treated With Ruxolitinib (RUX): Data From the Veterans Affairs Corporate Data Warehouse (VACDW)
Mascarenhas, John
Perkins, Aaron R.
Shih, Yu-Hsuan
Tang, Derek
Vergara, Sara
Alvarez, Carlos A.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S422 - S422
[22] A Phase 1 Study of INCB057643 Monotherapy in Patients with Relapsed or Refractory Myelofibrosis (INCB 57643-103).
Vachhani, Pankit
Lihou, Christine
Zhou, Gongfu
Zheng, Fred
CANCER RESEARCH, 2021, 81 (13)
[23] Phase 3 trial of momelotinib (MMB) vs ruxolitinib (RUX) in JAK inhibitor (JAKi) naive patients with myelofibrosis (MF).
Mesa, Ruben A.
Kiladjian, Jean -Jacques
Catalano, John V.
Devos, Timothy
Egyed, Miklos
Hellman, Andrzei
McLornan, Donal
Shimoda, Kazuya
Winton, Elliott F.
Deng, Wei
Dubowy, Ronald L.
Maltzman, Julia D.
Cervantes, Francisco
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[24] Dosing Pattern of Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) in Italy: Results from a Prospective Observational Study (ROMEI)
Breccia, Massimo
Guglielmelli, Paola
Mendicino, Francesco
Malato, Alessandra
Palumbo, Giuseppe A.
Seller, Carmine
Cilloni, Daniela
Mazza, Patrizio
Siragusa, Sergio
Abruzzese, Elisabetta
Martelli, Maurizio
Benevolo, Giulia
Rinaldi, Erminia
Crugnola, Monica
Rupoli, Serena
Pavone, Vincenzo
Bonifacio, Massimiliano
Pane, Fabrizio
Carli, Giuseppe
Langella, Maria
Ventre, Marta Bruno
Elli, Elena Maria
Impera, Stefana
Liberati, Anna Marina
Di Renzo, Nicola
Martino, Bruno
Sportoletti, Paolo
Tiribelli, Mario
Binotto, Gianni
Annunziata, Mario
Di Ianni, Mauro
La Nasa, Giorgio
Falcone, Antonietta Pia
Leanza, Rossana
Volpe, Antonio
Gherlinzoni, Filippo
De Stefano, Valerio
Vallisa, Daniele
Crescenzi, Sabrina Leonetti
Cavazzini, Francesco
Ricco, Alessandra
Barberio, Carmela
Misto, Alessandra
Passamonti, Francesco
Palandri, Francesca
BLOOD, 2022, 140 : 9688 - 9690
[25] A phase II study of cpi-0610, a bromodomain and extraterminal protein inhibitor (BETi) alone or with ruxolitinib (RUX), in patients with myelofibrosis (MF).
Kremyanskaya, Marina
Hoffman, Ronald
Mascarenhas, John
Bose, Prithviraj
Gupta, Vikas
Schiller, Gary J.
Liew, Elena
Lebedinsky, Claudia
Senderowicz, Adrian Mario
Mertz, Jennifer
Trojer, Patrick
Verstovsek, Srdan
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[26] Fedratinib (FEDR) in patients with myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF) previously treated with Ruxolitinib (RUX): a reanalysis of the phase 2 Jakarta-2 study
Reiter, A.
Harrison, C. N.
Doehner, K.
Heidel, F.
Gisslinger, H.
Niederwieser, D.
Schaap, N.
Vannucchi, A. M.
Kiladjian, J. -J.
Jourdan, E.
Silver, R. T.
Schouten, H. C.
Passamonti, F.
Zweegman, S.
Talpaz, M.
Verstovsek, S.
Gerike, T.
Rose, S.
Li, M.
Brownstein, C.
Mesa, R. A.
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 91 - 92
[27] Final Results of Ruxopeg, a Phase 1/2 Adaptive Randomized Trial of Ruxolitinib (Rux) and Pegylated Interferon Alpha (IFNa) 2a in Patients with Myelofibrosis (MF)
Kiladjian, Jean-Jacques
Ianotto, Jean-Christophe
Soret, Juliette
Maslah, Nabih
Chaffaut, Cendrine
Perrard, Francoise Boyer
Barraco, Fiorenza
Dubruille, Viviane
Capron, Claude
Tisserand, Amandine
Rolland-Neyret, Valerie
Ghrieb, Zineb
Chevret, Sylvie
Plo, Isabelle
Schlageter, Marie-Helene
Meignin, Veronique
Resche-Rigon, Matthieu
Cassinat, Bruno
BLOOD, 2022, 140
[28] Long term follow-up results of phase II clinical trial evaluating ruxolitinib (RUX) and azacitidine (AZA) combination therapy in patients (pts) with myelofibrosis (MF).
Arora, Sankalp
Senapati, Jayastu
Masarova, Lucia
Pemmaraju, Naveen
Bose, Prithviraj
Bravo, Guillermo Montalban
Saenz, Dyana T.
Halim, Habiba
Zhou, Lingsha
Maiti, Abhishek
Borthakur, Gautam
Kadia, Tapan M.
Jabbour, Elias
Garcia-Manero, Guillermo
Kantarjian, Hagop M.
Daver, Naval Guastad
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[29] Long-term outcomes of ruxolitinib (RUX) therapy in patients (pts) with myelofibrosis (MF): 5-year update from COMFORT-I.
Gupta, Vikas
Verstovsek, Srdan
Mesa, Ruben A.
Gotlib, Jason R.
DiPersio, John F.
Catalano, John V.
Deininger, Michael W. N.
Miller, Carole Brennan
Silver, Richard T.
Talpaz, Moshe
Winton, Elliott F.
Harvey, Jimmie Huling
Arcasoy, Murat.
Hexner, Elizabeth O.
Lyons, Roger M.
Paquette, Ronald
Raza, Azra
Kornacki, Deanna
Sun, Kang
Kantarjian, Hagop M.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[30] Real-world (RW) clinical outcomes of patients (pts) with myelofibrosis (MF) treated with ruxolitinib (RUX): evidence from a multinational medical record review
Heidel, F. H.
Passamonti, F.
Parikh, R. C.
Tang, D.
Lahue, B. J.
Nadal, J. A.
Davis, K. L.
Ajmera, M.
Kee, A.
Abraham, P.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 161 - 162

← 1 2 3 4 5 →